Estrella Immunopharma (ESLA) Competitors $0.90 -0.05 (-5.00%) Closing price 07/25/2025 03:59 PM EasternExtended Trading$0.89 -0.01 (-1.33%) As of 07/25/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. ALTS, PLX, SAVA, GNLX, FTLF, ACTU, SKYE, HURA, CTOR, and ONCYShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include ALT5 Sigma (ALTS), Protalix BioTherapeutics (PLX), Cassava Sciences (SAVA), Genelux (GNLX), FitLife Brands (FTLF), Actuate Therapeutics (ACTU), Skye Bioscience (SKYE), TuHURA Biosciences (HURA), Citius Oncology (CTOR), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Its Competitors ALT5 Sigma Protalix BioTherapeutics Cassava Sciences Genelux FitLife Brands Actuate Therapeutics Skye Bioscience TuHURA Biosciences Citius Oncology Oncolytics Biotech Estrella Immunopharma (NASDAQ:ESLA) and ALT5 Sigma (NASDAQ:ALTS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings. Do insiders & institutionals hold more shares of ESLA or ALTS? 0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by company insiders. Comparatively, 4.9% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, ESLA or ALTS? Estrella Immunopharma has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Does the media prefer ESLA or ALTS? In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 2 articles in the media. Estrella Immunopharma's average media sentiment score of 1.32 beat ALT5 Sigma's score of 0.94 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ESLA or ALTS? Estrella Immunopharma presently has a consensus target price of $16.00, suggesting a potential upside of 1,673.84%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Estrella Immunopharma is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings and valuation, ESLA or ALTS? ALT5 Sigma has higher revenue and earnings than Estrella Immunopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.47ALT5 Sigma$12.53M9.86-$6.24MN/AN/A Is ESLA or ALTS more profitable? Estrella Immunopharma has a net margin of 0.00% compared to ALT5 Sigma's net margin of -38.58%. ALT5 Sigma's return on equity of -113.79% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -1,132.38% -273.91% ALT5 Sigma -38.58%-113.79%-8.96% SummaryEstrella Immunopharma and ALT5 Sigma tied by winning 6 of the 12 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.34M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-3.4721.1828.1020.05Price / SalesN/A288.50432.4490.07Price / CashN/A42.7636.2258.56Price / Book7.528.378.665.87Net Income-$7.31M-$55.19M$3.25B$258.55M7 Day Performance5.72%5.88%4.23%3.74%1 Month Performance-4.04%17.33%10.52%11.75%1 Year Performance-59.19%4.42%34.41%18.03% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma3.2141 of 5 stars$0.90-5.0%$16.00+1,673.8%-47.9%$34.34MN/A-3.47N/ANews CoverageGap DownALTSALT5 Sigma0.1244 of 5 stars$7.22-2.0%N/A+254.0%$125.99M$12.53M0.00170PLXProtalix BioTherapeutics2.9323 of 5 stars$1.58+3.9%$15.00+849.4%+31.3%$125.78M$59.76M-12.15200SAVACassava Sciences4.1505 of 5 stars$2.58+12.2%$54.50+2,012.4%-81.6%$124.64MN/A-1.7230Positive NewsGNLXGenelux1.2216 of 5 stars$3.30-6.0%$17.75+437.9%+74.0%$124.61M$10K-3.7510Analyst ForecastFTLFFitLife Brands4.0874 of 5 stars$13.25+2.2%$20.50+54.7%-23.6%$124.42M$64.47M15.7720News CoverageACTUActuate Therapeutics2.252 of 5 stars$6.26+10.6%$20.50+227.5%N/A$122.82MN/A0.0010News CoverageSKYESkye Bioscience2.4213 of 5 stars$3.88+4.0%$16.60+327.8%-33.7%$120.20MN/A-4.7311News CoverageHURATuHURA Biosciences1.7846 of 5 stars$2.74+7.5%$12.67+362.3%N/A$119.68MN/A0.00N/ACTORCitius Oncology1.7523 of 5 stars$1.65+11.5%$3.00+81.8%N/A$118.06MN/A0.00N/APositive NewsAnalyst UpgradeGap UpONCYOncolytics Biotech1.8147 of 5 stars$1.24+2.5%$4.33+249.5%+1.0%$116.91MN/A-4.2830News CoverageUpcoming Earnings Related Companies and Tools Related Companies ALT5 Sigma Competitors Protalix BioTherapeutics Competitors Cassava Sciences Competitors Genelux Competitors FitLife Brands Competitors Actuate Therapeutics Competitors Skye Bioscience Competitors TuHURA Biosciences Competitors Citius Oncology Competitors Oncolytics Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESLA Stock Alerts